YOUR LENTIVIRUS
SPECIALIZED PARTNER
Lentiviral vectors for gene therapy
DEVELOPMENT AND MANUFACTURING
GMP-SOLUTIONS CDMO
Our main aim is to adapt to your own requirements from a technical and timeline perspective
TECHNOLOGY
OWN TECHNOLOGY DEVELOPMENT
Our main aim is to implement a technology development strategy focused on providing a response to the main hurdles that currently exist within the gene therapy field
LATEST NEWS
23 September 2019
VIVEbiotech makes a capital increase of 3.5 million euros to complete its expansion plan
06 September 2019
The Minister of Health visits VIVEbiotech
CONTACT OUR EXPERTS FOR FURTHER DISCUSSION
